[Articles] Cabozantinib monotherapy for advanced adrenocortical carcinoma: a single-arm, phase 2 trial

April, 04, 2024 | Select Oncology Journal Articles

Cabozantinib in advanced adrenocortical carcinoma showed promising efficacy with a manageable and anticipated safety profile. Further prospective studies with cabozantinib alone and in combination with immune checkpoint therapy are ongoing.

For Additional News from OncWeekly – Your Front Row Seat To The Future of Cancer Care –




Sign up for our emails

Trusted insights straight to your inbox and get the latest updates from OncWeekly

Privacy Policy